Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B.J. Kuss

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

Hematological Oncology

English

An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies

Hematological Oncology

English

Related publications

Patterns of Duvelisib-Induced Lymphocytosis in Patients With R/R CLL or SLL Including Those With High-Risk Factors Treated in the Duo Trial

Hematological Oncology

English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

English

Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial

Hematological Oncology

English

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2015

English

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Hematological Oncology

English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

English

Real-World Results of Ibrutinib in Relapsed/Refractory CLL in France: Early Results on a Large Series of 428 Patients

American Journal of Hematology

Hematology

2017

English

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Hematological Oncology

English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by B.J. Kuss

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies

Related publications

Patterns of Duvelisib-Induced Lymphocytosis in Patients With R/R CLL or SLL Including Those With High-Risk Factors Treated in the Duo Trial

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Characterization of Duvelisib in Patients With Refractory Marginal Zone Lymphoma: Data From the Phase 2 Dynamo Trial

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

The PI3Kδ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Real-World Results of Ibrutinib in Relapsed/Refractory CLL in France: Early Results on a Large Series of 428 Patients

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina